JosephRonaldMaceMD

Oncology • Saint Petersburg, FL

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Physician

Join to view full profile

Dr. Mace is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mace's full profile

Already have an account?

Office
1201 5th Ave N
Ste 505
Saint Petersburg, FL 33705
Phone+1 727-821-0017

Fax+1 727-502-8861

Education & Training

University of MichiganFellowship, Hematology and Medical Oncology, 1999 - 2002
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1996 - 1999
University of Pennsylvania Health SystemResidency, Radiology-Diagnostic, 1994 - 1996
St Joseph's HealthInternship, Transitional Year, 1993 - 1994
SUNY Upstate Medical UniversityClass of 1993

Certifications & Licensure

FL State Medical License 2002 - 2025
NY State Medical License 1999 - 2004
MI State Medical License 1998 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2014

Clinical Trials

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
Completed
Phase 2

Publications & Presentations

PubMed

123 citations
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a ra...
Thierry Facon, Shaji Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau
The Lancet. Oncology. 2021-10-13
8 citations
A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-...
Jesus G. Berdeja, Tara K. Gregory, Edward A. Faber, Lowell L. Hart, Joseph R. Mace
American Journal of Hematology. 2021-01-09
11 citations
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy
Ian W. Flinn, Jack Erter, Davey B. Daniel, Joseph R. Mace, Jesus G. Berdeja
The Oncologist. 2019-08-01

Lectures

Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Lucio N. Gordan, MD Discusses Findings of Phase 3 Clinical Trial Supporting Advanced Treatments for Multiple Myeloma in National BroadcastApril 26th, 2024